Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-titer vs standard-titer convalescent plasma in hospitalized COVID-19 patients
NCT04524507Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Aug 2020
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19), sponsored by University of North Carolina at Chapel Hill. Started Aug 2020; status: completed.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04524507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04524507.